bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023

Mar 23, 2023 | Press Releases

SAN ANTONIO, Texas (March 24, 2023) – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close. The Company will host a conference call on Monday, April 3, 2023, at 9:00 a.m. Eastern time to discuss those results and answer questions.

Event: bioAffinity Technologies Fourth Quarter 2022 Financial Results
Date: Monday, April 3, 2023
Time: 9:00 a.m. EDT
Toll Free: 1-877-270-2148
International: 1-412-902-6510
Webcast: Webcast link


A replay of the event will be available for 90 days at the webcast link above, which can also be found in the Investor Relations section of bioAffinity’s website at

About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. The Company’s first product, CyPath® Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. Precision Pathology Services licensed and developed CyPath® Lung as a Laboratory Developed Test (LDT) and has begun test marketing in Texas. OncoSelect® Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. Research and optimization of the Company’s platform technologies are conducted in its laboratories at The University of Texas at San Antonio.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Company’s offering of common shares. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release except as may be required by applicable securities laws.

bioAffinity Technologies
Julie Anne Overton
Director of Communications

LHA Investor Relations
Tirth T. Patel


Recent Posts

Learn About CyPath Lung

CyPath Lung Test